バセドウ病の世界市場規模：診断別、治療別、地域別、予測

バセドウ病の市場規模と予測

バセドウ病市場規模は2024年に3億6,266万米ドルと評価され、2026～2032年にかけてCAGR 4.82%で成長し、2032年には5億1,877万米ドルに達すると予測されています。

バセドウ病の世界市場促進要因

バセドウ病市場の市場促進要因は、様々な要因の影響を受ける可能性があります。これらには以下が含まれます。

• バセドウ病の有病率の増加：主要因の1つは、甲状腺機能亢進症を引き起こす自己免疫疾患であるバセドウ病の有病率が上昇していることです。より多くの症例が診断されるにつれて、効率的な治療法の必要性が高まっている
• 治療法の改善：バセドウ病の治療法は、内分泌学の研究開発の結果、より優れた新しい治療法が開発されています。生物製剤や低分子薬などの薬剤療法の革新は、患者さんの転帰と治療効果を改善しています。
• より優れた診断法：バセドウ病の早期かつ正確な診断は、自己抗体検査や甲状腺機能検査など、診断の技術的進歩によって可能になりました。管理と治療を効果的に行うためには、早期診断が不可欠です。
• 知識と教育の向上：バセドウ病に対する一般の人々や医療界の理解が深まることで、より多くの診断がなされ、迅速な治療が行われるようになります。患者支援団体や教育キャンペーンは、症状や利用可能な治療法についての認識を高めるための重要な手段です。
• 人口の高齢化：バセドウ病やその他の自己免疫疾患は、世界の高齢化の結果、より一般的になってきています。自己免疫疾患は高齢者に多く、治療の必要性が高まっている
• ヘルスケアへのアクセスの増加：特に発展途上国では、ヘルスケアサービスへのアクセスが向上した結果、バセドウ病の診断・治療例が増加しています。この傾向は、ヘルスケアのインフラを改善しようとする政府の取り組みやヘルスケア改革によって促進されています。
• 個別化医療へのニーズの高まり：個別化医療はますます普及しています。これは、患者の遺伝的、環境的、ライフスタイル的特徴に基づいて治療を決定するものです。この方法は、バセドウ病などの自己免疫疾患の治療に非常に有効です。
• 未治療の病気の経済的負担：甲状腺眼症や心血管障害などの合併症を含め、バセドウ病の未治療や不十分な管理によって生じる経済的負担が大きいため、このような高価な合併症を回避できる効率的な治療が必要とされています。
• バセドウ病治療の現状を改善し、新しい治療法の開発を促進するためには、製薬企業だけでなく、公的機関や民間企業からの研究開発への資金提供の増加が役立ちます。
• 技術革新：バセドウ病患者は、標的療法や徐放性製剤などのドラッグデリバリー法の技術開発により、より便利で効果的な治療選択肢を得ることができます。

世界のバセドウ病市場抑制要因

バセドウ病市場にとって、いくつかの要因が抑制要因または課題として作用する可能性があります。これらには以下が含まれます。

• 高価な治療：高価な治療：薬剤療法、放射性ヨード療法、手術はすべて、バセドウ病の高額な治療の一部です。法外な出費は、特に保険やヘルスケアに対する資金が乏しい地域では、患者がこれらの治療を受けることを妨げる可能性があります。
• 放射性ヨード、抗甲状腺薬、甲状腺切除術を含むバセドウ病の治療には、重篤な副作用があり、安全性に問題がある場合があります。このような副作用のために使用が制限され、患者が服薬をやめたり、治療計画を守らなかったりすることがあります。
• 制限された知識と診断：一般の人々や一部の医療従事者は、バセドウ病に関する知識や理解が乏しいことが多いです。診断や治療の遅れは、患者の転帰や市場の需要に影響を与える可能性があります。
• 厳しい規制基準：バセドウ病の新薬は厳しい規制基準に合格しなければならず、その製造には費用と時間がかかります。規制上の障害は、新規治療の発売を延期し、関連費用を増加させる可能性があります。
• 代替療法との競合：放射性ヨード治療、抗甲状腺薬、手術は、バセドウ病の治療法として実績のあるもの一部です。市場に受け入れられるためには、新しい治療法がこれらの現在の治療法よりも有意に有益であることを示さなければならないが、それは難しい可能性があります。
• 治療反応のばらつき：バセドウ病では、様々な治療法に対する反応が個人によって異なるため、どの治療法が患者さんにとって最も効果的かを判断することが困難です。このような予測不可能性は、治療計画をより困難にし、治療の全体的な成功率を低下させる可能性があります。
• 最小限の研究開発：他の慢性疾患と比較すると、バセドウ病の患者数は非常に少ないため、新しい治療法の研究開発は少ないかもしれません。そのため、治療法の進歩や上市の妨げになる可能性があります。
• 経済的制約：バセドウ病に対する高価な治療法の採用は、景気後退やヘルスケアシステムの予算制限によって影響を受ける可能性があります。景気後退期には、公共部門や商業部門からの新規治療に対する資金調達が制約される可能性があります。
• 保険と決済の問題：バセドウ病治療に対する保険適用と決済は、より新しく、より高額な治療に関しては、ばらつきがあります。患者の自己負担が大きいと、可能な限り最良の治療を受けようとしない可能性があります。
• 患者のコンプライアンス：長期にわたる医薬品の使用とバセドウ病の慢性的な性質が相まって、患者のコンプライアンスに問題が生じることがあります。頻繁なモニタリングの必要性や重篤な副作用の可能性により、治療法の遵守が影響を受ける可能性があります。

目次

第1章 世界のバセドウ病市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のバセドウ病市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 バセドウ病の世界市場：エンドユーザー別

• 概要
• 病院
• 専門クリニック
• 外来手術センター
• 在宅医療

第6章 バセドウ病の世界市場：治療別

• 概要
• 抗甲状腺薬
• 放射性ヨード療法
• ベータ遮断薬
• 手術療法
• 補助療法
• 新しい治療法

第7章 バセドウ病の世界市場：流通チャネル別

• 概要
• 病院薬局
• 小売薬局
• オンライン薬局
• 専門薬局

第8章 バセドウ病の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東

第8章 世界のバセドウ病市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第9章 企業プロファイル

• Merck & Co., Inc.
• Abbott Laboratories
• Pfizer, Inc.
• GlaxoSmithKline plc
• Allergan, plc
• RLC LABS
• Mylan N.V.
• AbbVie, Inc.

第10章 付録

• 関連調査"

Graves Disease Market Size And Forecast

Graves Disease Market size was valued at USD 362.66 Million in 2024 and is projected to reach USD 518.77 Million by 2032, growing at a CAGR of 4.82% from 2026 to 2032.

Global Graves Disease Market Drivers

The market drivers for the Graves Disease Market can be influenced by various factors. These may include:

• Growing Prevalence of Graves' Disease: One of the main causes is the rising prevalence of Graves' disease, an autoimmune condition that causes hyperthyroidism. The need for efficient therapies is increasing as more instances are diagnosed.
• Improvements in Treatment Options: New and better treatments for Graves' disease have been developed as a result of ongoing endocrinology research and development. Drug therapy innovations, such as biologics and small molecule medications, improve patient outcomes and treatment efficacy.
• Better Diagnostic Methods: The early and more accurate diagnosis of Graves' disease is made possible by technological advancements in diagnostics, such as less intrusive and more accurate tests for autoantibodies and thyroid function. For management and treatment to be effective, early diagnosis is essential.
• Enhanced Knowledge and Education: A greater public and medical community understanding of Graves' illness results in a greater number of diagnoses and prompt medical management. Patient advocacy groups and educational campaigns are important tools for raising awareness of the symptoms and available treatments.
• Ageing Population: Graves' disease and other autoimmune disorders are becoming more common as a result of the world's ageing population. Autoimmune disorders are more common in older persons, which increases the need for medical treatments.
• Increased Access to Healthcare: More cases of Graves' illness are diagnosed and treated as a result of improved access to healthcare services, especially in developing nations. This tendency is facilitated by government initiatives and healthcare reforms that attempt to improve the infrastructure of healthcare.
• Growing Need for Personalised Medicine: Personalised medicine is becoming more and more popular. It bases treatment decisions on a patient's genetic, environmental, and lifestyle characteristics. This method is very useful for treating autoimmune conditions such as Graves' disease.
• Economic Burden of Untreated illness: The need for efficient treatments that can avert these expensive complications is driven by the significant economic burden that results from untreated or inadequately managed Graves' illness, including complications like thyroid eye disease and cardiovascular problems.
• Increased financing for research and development from public and private institutions as well as pharmaceutical corporations helps to improve the current landscape of treatments for Graves' disease and encourage the development of new treatment modalities.
• Technological Innovations: Patients with Graves' disease benefit from more convenient and effective treatment options thanks to technological developments in drug delivery methods, including as targeted therapy and sustained-release formulations.

Global Graves Disease Market Restraints

Several factors can act as restraints or challenges for the Graves Disease Market. These may include:

• Expensive Treatment: Medication, radioactive iodine therapy, and surgery are all part of the costly treatment for Graves' illness. Exorbitant expenses may prevent patients from receiving these therapies, particularly in areas with little insurance or financing for healthcare.
• Treatments for Graves' illness, including radioactive iodine, antithyroid drugs, and thyroidectomy, can have serious adverse effects and raise safety issues. These side effects may restrict their use and cause patients to stop taking their medication or not comply with their treatment plan.
• Restricted Knowledge and Diagnosis: The general public, as well as some healthcare professionals, frequently have a poor knowledge and comprehension of Graves' illness. Delayed diagnosis and treatment might have an impact on patient outcomes and market demand.
• Strict Regulatory criteria: New medicines for Graves' disease must pass strict regulatory criteria, which can be expensive and time-consuming to produce. Regulatory obstacles have the potential to postpone the launch of novel treatments and raise their associated expenses.
• Competition from Alternative Therapies: Radioactive iodine therapy, antithyroid medications, and surgery are some of the proven treatments for Graves' illness. To be accepted by the market, new treatments must shown to be significantly more beneficial than these current options, which might be difficult.
• Variability in Treatment Response: Individuals with Graves' illness may react differently to various therapies, making it challenging to determine which course of action will work best for each patient. This unpredictability can make treatment plans more difficult to follow and lower the overall success rates of therapy.
• Minimal Research and Development: Compared to other chronic diseases, Graves' disease patients are very small, hence research and development for novel treatments may be scarce. This may impede the rate of advancement and the launch of novel treatments.
• Economic Constraints: The adoption of expensive therapies for Graves' disease may be impacted by downturns in the economy and budgetary restrictions in healthcare systems. During recessions, financing for novel treatments from the public and commercial sectors may be constrained.
• Problems with Insurance and payment: When it comes to newer and more costly therapies, insurance coverage and payment for Graves' disease treatments can be uneven. Significant out-of-pocket expenses for patients may discourage them from obtaining the best care possible.
• Patient Compliance: Long-term pharmaceutical use combined with the chronic nature of Graves' illness may cause problems with patient compliance. Adherence to treatment methods may be impacted by the necessity for frequent monitoring and the possibility of serious adverse effects.

Global Graves Disease Market: Segmentation Analysis

The Global Graves Disease Market is Segmented on the basis of Treatment Type, End-User, Distribution Channel, and Geography.

Graves Disease Market, By Treatment Type

• Anti-Thyroid Medications: Drugs used to reduce the production of thyroid hormones. Common medications include methimazole (Tapazole) and propylthiouracil (PTU).
• Beta-Blockers: Medications that help manage symptoms such as rapid heart rate, tremors, and anxiety. Examples include propranolol and atenolol.
• Radioactive Iodine Therapy: A treatment that involves ingesting radioactive iodine to destroy overactive thyroid cells, reducing thyroid hormone production.
• Surgery (Thyroidectomy): A surgical procedure to remove all or part of the thyroid gland, typically used when other treatments are not suitable or effective.
• Adjunctive Therapies: Supportive treatments including corticosteroids to manage inflammation and immune responses associated with Graves' disease.
• Emerging Treatments: New therapies under development, including biologics and targeted therapies aimed at the underlying autoimmune aspects of the disease.

Graves Disease Market, By End-User

• Hospitals: Facilities where comprehensive treatment options including surgery and radioactive iodine therapy are provided.
• Specialty Clinics: Clinics specializing in endocrinology and thyroid disorders offering specialized care and treatment plans for Graves' disease.
• Ambulatory Surgical Centers: Outpatient facilities where surgical treatments such as thyroidectomy can be performed.
• Homecare Settings: For patients managing their condition with medications and regular monitoring at home.

Graves Disease Market, By Distribution Channel

• Hospital Pharmacies: Pharmacies located within hospitals that dispense medications and provide treatment-related supplies.
• Retail Pharmacies: Community pharmacies where patients can obtain prescribed medications.
• Online Pharmacies: E-commerce platforms providing an accessible way for patients to order and receive their medications.
• Specialty Pharmacies: Pharmacies that focus on complex and chronic conditions, offering personalized services and specialized medications.

Graves Disease Market, By Geography

• North America: A major market driven by a high prevalence of autoimmune diseases, advanced healthcare infrastructure, and significant R&D activities.
• Europe: A significant market with growing awareness and diagnosis of thyroid disorders, supported by robust healthcare systems.
• Asia-Pacific: A rapidly growing market due to increasing healthcare access, rising prevalence of thyroid disorders, and improving healthcare infrastructure.
• Latin America: An emerging market with increasing healthcare investments and growing awareness about thyroid health.
• Middle East and Africa: A developing market with improving healthcare facilities and increasing efforts to diagnose and treat thyroid disorders.

Key Players

The "Global Graves Disease Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Merck & Co., Inc., Abbott Laboratories, Pfizer, Inc., GlaxoSmithKline plc, Allergan, plc, RLC LABS, Mylan N.V., AbbVie, Inc., F .Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Jubilant Pharma Holdings Inc., Apitope International NV, Quintiles Inc., Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL GRAVES DISEASE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL GRAVES DISEASE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL GRAVES DISEASE MARKET, BY End-User

• 5.1 Overview
• 5.2 Hospitals
• 5.3 Specialty Clinics
• 5.4 Ambulatory Surgical Centers
• 5.5 Homecare Settings

6 GLOBAL GRAVES DISEASE MARKET, BY TREATMENT

• 6.1 Overview
• 6.2 Anti-Thyroid Medication
• 6.3 Radioactive Iodine Therapy
• 6.4 Beta-Blockers
• 6.6 Surgery
• 6.7 Adjunctive Therapies
• 6.8 Emerging Treatments

7 GLOBAL GRAVES DISEASE MARKET, BY Distribution Channel

• 7.1 Overview
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Pharmacies
• 7.6 Specialty Pharmacies

8 GLOBAL GRAVES DISEASE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East

8 GLOBAL GRAVES DISEASE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Merck & Co., Inc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Abbott Laboratories
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Pfizer, Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 GlaxoSmithKline plc
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Allergan, plc
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 RLC LABS
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Mylan N.V.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 AbbVie, Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments

10 Appendix

• 10.1 Related Research"